218 results about "PHA binding" patented technology

The present invention describes a method for identification and labeling of sentinel lymph nodes (SLNs) and the presence or absence of lymph node metastases as an important diagnostic and prognostic factor in early stage cancers of all types. The method, know as Molecular Lymphatic Mapping, uses traditional dye/radioactive tracer based techniques in conjunction with a nucleic acid marker to identify and label the SLN, not only for current diagnostic methods, but for archival purposes. In addition, MLM can be used to deliver a therapeutic gene or genes to the SLN to activate tumor immunity to tumor cells, and/or to inhibit tumor metastases. The methods may be combined with therapeutic intervention including chemotherapy and radiotherapy.

The invention relates to the field of biological medicine and particularly relates to an anti-human PD-1 humanized monoclonal antibody and application thereof. By virtue of sieving, the anti-human PD-1 humanized monoclonal antibody with favorable specificity and relatively high compatibility and stability is obtained, can be specifically combined with human PD-1, but is not combined with other members of the CD28 family, is capable of blocking combination of PD-L1 and PD-1 and partially restoring functions of T cells, and has an obvious inhibiting effect on tumor growth.

The invention combines a novel combination with two especially important aspects: first, the invention proposes to simultaneously stimulate response in white blood cells and a patient's tumor cells with a mitogen-challenging compound, preferably a lectin, in the preferred mode the selected lectin being phytohemagglutin ("PHA"), and second, to generate heat shock protein. A method of treatment is set out. The method of manufacturing proposed utilizes a system calculated to better insure sterility and streamline production of the cytokine modulator. A method of testing in conjunction with the therapy is also claimed utilizing clinical assessment of disease activity, patient performance status, and quality of life questionnaire. Should efficacy of a treatment fall off, particularly because of mutation or adaption, the composition and method may be re- applied. The invention is not limited to humans, but is also applicable to mammals. The composition is usable as a stand-alone composition, but preferably is used in conjunction with standard therapy such as radiation, chemotherapy or surgery, particularly surgical therapy, and in conjunction with the administration of cystine, as later defined, to enhance immune system competency.

The invention relates to a magnetic particle chemiluminescence immunoassay method for human thyroglobulin antibodies (TGAb) and belongs to the technical field of immunoassay. TG antigens marked by fluorescein isothiocyanate (FITC) and human IgG antibodies marked by alkaline phosphatase are combined to form an antigen-antibody-second enzyme-labeled antibody sandwich immune complex with a sandwich-like structure. Then, magnetic particles connected with FITC antibodies are added, the antigen-antibody complex is connected to the magnetic particles through specific combination of the FITC antibodies and the FITC and directly deposited in an external magnetic field, and the complex formed by immune reaction can be separated from the other non-combined substances without centrifuging. A kit combines chemiluminescence with the magnetic particles to provide a reaction system close to a homogeneous phase. Compared with the prior art, the kit has the advantages of higher sensitivity, wide linear range, quickness and the like; the cost of a product is greatly reduced; and the kit has a broad application prospect on the aspects of clinical examination and the like.

The invention discloses a kit for quantitatively testing free triiodothyronine, which comprises 3,3'-L-Diiodothyronine-gelatin enveloped magnetic bead suspension, a free triiodothyronine series calibrator, a horse radish peroxidase labeled free triiodothyronine antibody, chemiluminescent substrate A solution, chemiluminescent substrate B solution, and PBS buffer solution. The invention also discloses a method for preparing the kit. The kit has the advantages that: the chemiluminescence technology is combined with the immunomagnetic bead technology, the immunomagnetic beads are taken as a reaction carrier, the effective envelop amount of antigen is increased, raw materials are saved and the detection sensitivity and detection speed are obviously improved. A method for enveloping antigen analogs by the labeled antibody is adopted, so the analogs can be specifically combined with the antibody of hormone, but the combination capacity with thyroxine-binding protein is greatly reduced, and the influence of the binding protein on a measurement system is reduced to a large extent.

The invention relates to the technical field of biology, and particularly discloses a canine single-chain antibody, and a construction method and application thereof. By designing the canine antibody variable region degenerate primers, the canine heavy chain variable region VH and light chain variable region VL genes are successfully amplified. On such basis, a bacteriophage display technique is utilized to successfully construct the canine single-chain antibody scFv library. The scFv single-chain antibody library has diversity and enough storage capacity. A Dot-ELISA method is utilized to screen 3 single chain antibodies capable of being combined with the canine DEA 1.1 blood group antigen from the scFv single-chain antibody library by using the canine DEA 1.1 blood group antigen, wherein Clone 16 has stronger combination characteristic. A pET-32a-Clone16 recombinant protein is constructed according to the Clone 16 gene to perform prokaryotic expression, and the purified antibody has combination activity. The canine single-chain antibody lays solid foundation for preparing canine DEA 1.1 blood grouping reagents.

The invention relates to the field of tumor immunology, in particular to construction and application of chimeric antigen receptor-T (CAR-T) cells capable of targeting mesothelin and carrying a PD-L1blocking agent. The CAR-T cells are constructed by transfecting a CAR capable of targeting the mesothelin and carrying the PD-L1 blocking agent, wherein the CAR capable of targeting the mesothelin andcarrying the PD-L1 blocking agent is formed by a leader peptide of a CD8 antigen, an anti-mesothelin single-chain antibody, a hinge region, a transmembrane region, an intracellular signal domain andan anti-PD-L1 antibody secretion region which are sequentially connected with one another. The mesothelin SS1P scFv of the CAR-T cells provided by the invention can specifically bind to tumor cells expressing mesothelin glycoprotein and promote the secretion of anti-tumor-related cytokines, thereby achieving a killing effect on the tumor cells; furthermore, the CAR-T cells provided by invention can also secrete a PD-L1 antibody, specifically bind to PD-L1 produced by tumor cell expression, and block the inhibitory effect of a PD-L1/PD-1 signal on T cell activity, thus facilitating the long-term effective inhibition of the CAR-T on tumor cell growth.

This invention provides a process for the continuous alkaline lysis of a bacterial suspension in order to harvest pDNA. It further provides for optional additional purification steps, including lysate filtration, anion exchange chromatography, triplex affinity chromatography, and hydrophobic interaction chromatography. These optional purification steps can be combined with the continuous lysis in order to produce a highly purified pDNA product substantially free of gDNA, RNA, protein, endotoxin, and other contaminants.

In some embodiments, the present disclosure pertains to a method of enhancing chimeric antigen receptor expressing T cell function. In some embodiments, the method comprises activating the chimeric antigen receptor expressing T cells. In some embodiments, the method further comprises determining the differential expression of at least one molecule on the chimeric antigen receptor T cells. In some embodiments, the method comprises targeting the at least one molecule. In some embodiments, the present disclosure pertains to a method of treating a tumor in a subject in need thereof. In some embodiments, the method comprises administering to the subject an infusion of chimeric antigen receptor expressing T cells. In some embodiments, the method further comprises determining the differential expression of at least one molecule on the chimeric antigen receptor T cells. In some embodiments, the method comprises targeting the at least one molecule, wherein the molecule is differentially expressed upon activation of the chimeric antigen receptor expressing T cells.

The invention discloses an anti-Her2/PD-1 bispecific antibody and a preparation method thereof, and belongs to the field of biotechnology. The anti-Her2/PD-1 bispecific antibody can bind to Her2 and bind to PD-1, and can effectively enhance immune response by blocking a Her2 and/or PD-1 signaling pathway, so that the anti-Her2/PD-1 bispecific antibody is possible to have a good effect of enhancingthe anti-tumor immune response.

According to a method for detecting the plasma protein binding rate of meropenem or imipenem by combining a liquid chromatography-mass spectrometry technology with an ultrafiltration technology, the liquid chromatography-tandem mass spectrometry detection technology is combined with the ultrafiltration technology, and the total concentration of meropenem or imipenem in plasma and the free concentration of drugs in ultrafiltrate are respectively detected. And an MOPs stabilizer is added during sample treatment, so that the problem of poor drug stability is solved, and the determination result is more accurate. The method can be used for rapidly detecting the protein binding rate of the drug at high throughput, and is particularly suitable for unstable drug molecules.

The invention discloses an application of a ginseng PgWRKY4X transcription factor in regulating and controlling the content of ginsenoside compounds in ginseng. The amino acid sequence of the ginsengPgWRKY4X transcription factor is as shown in SEQ ID No. 1. Experiments prove that the ginseng PgWRKY4X transcription factor can be combined with a promoter of a ginseng PgSE gene, so the expression ofa key enzyme PgSE on a ginsenoside synthesis pathway is improved, and the content of ginsenoside compounds in ginseng is further improved. The ginseng PgWRKY4X transcription factor, an encoding geneof the ginseng PgWRKY4X transcription factor and an overexpression recombinant vector containing the encoding gene can be used for regulating and increasing the content of ginsenoside compounds in ginseng.

The invention provides a novel integrated structure and system-based approach for drug target prediction that enables the large-scale discovery of new targets for existing drugs Novel computer-readable storage media and computer systems are also provided. Methods and systems of the invention use novel sequence order-independent structure alignment, hierarchical clustering, and probabilistic sequence similarity techniques to construct a probabilistic pocket ensemble (PPE) that captures even promiscuous structural features of different binding sites for a drug on known targets. The drug's PPE is combined with an approximation of the drug delivery profile to facilitate large-scale prediction of novel drug-protein interactions with several applications to biological research and drug development.

The invention mainly relates to polypeptide combined with Japanese encephalitis virus envelope protein and an application of the polypeptide. The sequence of the polypeptide is HRHHV, and is linear binding polypeptide, a polypeptide sequence serves as a core, the polypeptide sequence can be prolonged and modified, and modification materials comprise but are not limited to nanometer materials, fluorescent materials, enzymes, biotin and specific protein. Based on the phage peptide library screening technology, several rounds of screening are carried out through expressed and purified Japanese encephalitis virus envelope protein, and finally a polypeptide clone strain capable of being specifically combined with Japanese encephalitis virus envelope protein can be obtained. The clone strain is selected for sequence determination, and the core sequence of the polypeptide is HRHHV. The polypeptide is artificially synthesized for an ELISA binding experiment, and a result proves that the synthesized polypeptide can be combined with Japanese encephalitis virus envelope protein well. Compared with the process of artificially expressing protein and then carrying out immunization to obtain a protein antibody, the polypeptide is simple and convenient, and operation is easier. As the polypeptide is marked, and qualitative and quantitative detection can be fast carried out on Japanese encephalitis virus envelope protein.

The invention discloses a reversibly assembled and disassembled Strep-tag polypeptide-labeled biomolecule derivatization matrix and an application thereof. Polypeptide can be linked on the surfaces of different matrixes on the basis of the characteristic that Strep-tag polypeptide can be bound to a matrix loaded with Strep-Tactin protein. Chemical derivatization is carried out on biological targeting molecules so as to form a biomolecule-Strep-tag conjugate; by virtue of specific recognition effects of the Strep-tag and the Strep-Tactin, the biomolecule-Strep-tag conjugate is immobilized on the surface of the matrix. After biotin is added, the linkage between the biomolecule and the matrix is destroyed due to the competitive binding between the biotin and the Strep-Tactin, so that reversible trapping and releasing on a to-be-detected object are achieved. The matrix is simple and rapid in preparing and using processes, good in repeatability, and is widely applicable to such fields of tumor marker detection, cell trapping and releasing, and the like.

The invention discloses a method applicable for blood cell high-flux fast classification analysis of common fishes such as crucian and carps. By aiming at the problem of white blood cell classification and counting interference by removing-incapable nucleated red blood cells in two aspects of the quantity and the form, an automatic measurement and analysis strategy of combining the fluorochrome with the multi-channel images is utilized; the interference red blood cell sampling points are separated from the white blood cells according to the differences of particles in the cells, cell nucleus forms, positions and the like; different white blood cell class group range of lymphocyte, monocyte, particle cells and the like undertaking important immunologic functions is divided; the automatic analysis is completed. The difficulty that the nucleated red blood cells cannot be effectively removed troubles the automatic analysis of hemogram of various kinds of animals for a long time. The fluorochrome is combined with the imaging analysis; a high-flux and high-sensitivity measuring module of a multidimensional panoramic analyzer is used for accurately recognizing the red blood cell class groups; the interference is eliminated; the important technical support is provided for the focused analysis of the white blood cell class groups; wide application prospects are realized.

The invention provides an immunofluorecence technique based method for evaluating activities of cryptosporidium parvum and giardia. The method has the following beneficial effects: the accurate, quick, simple, convenient and low-cost high throughput immunofluorecence assay technique is established and is used for evaluating the activities of cryptosporidium parvum and giardia in the ultraviolet (UV) disinfectant fluid; evaluation of the activities of cryptosporidium parvum and giardia in the UV irradiated water is realized by mainly carrying out competitive immunobinding on anti-pyrimidine-dimer (TDs) monoclonal antibodies and the TDs, taking fluorescein isothiocyanate as a marker and immunoglobulin (IgG) as a fluorescent substrate and binding 4',6-diamidino-2-phenylindole, dihydrochloride (DAPI); compared with the fluorescent staining method for evaluating the effect of UV on inactivating cryptosporidium parvum and giardia, the method provided by the invention has such excellent characteristics as strong specificity, high sensitivity and low professional operation requirements; and the cryptosporidium parvum and giardia activity evaluation method system is perfected by binding the method provided by the invention with the fluorescent staining method and other methods, and the method provided by the invention can be widely applied to the fields such as water quality monitoring, disease control and epidemic prevention and the like.

The invention relates to a three-dimensional DNA nano-structure, an electrochemical biosensor as well as preparation methods and application thereof. The three-dimensional DNA nano-structure is a hexahedron structure, and the hexahedron structure can be structurally transformed to cause electrochemical signal transformation by being combined with different target molecules. Four vertexes of the bottom surface of the three-dimensional DNA nano-structure unit are immobilized on the surface of a gold electrode through self-assembly action. According to the invention, the DNA nano-structure is assembled on the surface of the electrode to constitute the novel electrochemical biosensor, the DNA with the hexahedron structure has the characteristics of high-specificity target molecule recognition property and high stability, so that the analysis performance of the electrochemical biosensor is improved. The electrochemical biosensor provided by the invention can realize detection of different to-be-detected objects such as thrombin, lysozyme and the like by replacing a DNA chain and is wide in application range.

The invention discloses the technical field related to biological immune in-vitro diagnosis of medical instruments, and particularly relates to a thyroglobulin antibody detection kit and a use methodthereof. The kit comprises a calibration product, a quality control product, an anti-reagent, a magnetic particle reagent, a luminous substrate and a cleaning solution which are independently packaged, wherein the anti-reagents comprise a fluorescein isothiocyanate labeled thyroglobulin coating antigen and an alkaline phosphatase labeled anti-thyroglobulin labeled antibody; the magnetic particle reagent is prepared by coupling magnetic particles and a goat anti-fluorescein isothiocyanate antibody; a chemiluminescence technology is combined with immunomagnetic particles, so that the detection sensitivity and precision are greatly improved, the detection range is expanded, and the reaction time is short; a plurality of samples can be simultaneously determined on a full-automatic chemiluminiscence instrument, high-throughput quick determination of the thyroglobulin antibody is realized, the performance is reliable, the sensitivity is high, the linear range is wide, and the kit can be matched with semi-automatic and full-automatic instruments for use.

The invention provides an enriching method for transcription factor target genes through co-immunoprecititation of protein beads. The method comprises the following steps: expressing transcription factor protein containing antigen labels, and subjecting the transcription factor protein containing antigen labels and monoclonal antibodies directed at the antigen labels to an immunoreaction so as toform antigen-antibody compounds; carrying out co-immunoprecititation on protein beads and the antigen-antibody compounds to form antigen-antibody-protein bead compounds which have absorbed transcription factor proteins; binding the antigen-antibody-protein bead compounds to DNA digested segments of genomes so as to remove DNA segments which can not bind to the transcription factors of the compounds, which means candidate target gene segments which can bind to the transcription factors are enriched; further constructing an insertion library of the enriched segments, and carrying out sequencingto obtain target genes of the transcription factors. According to the invention, the target genes capable of directly binding to transcription factor proteins can be obtained effectively from genomesthrough a simplified method thanks to the introduction of the beads and improvement to experimental steps.

A method for identifying molecules which mimic an idiotype of an autoimmune disease-associated auto-antibody (autoantibodies). The method comprises the following steps: (a) purifying autoantibodies from sera of one or more patients afflicted with the autoimmune disease; (b) binding the autoantibodies to a solid phase to form an affinity matrix; (c) contacting pooled plasma or B cells comprising immunoglobulins with the affinity matrix followed by removal of unbound plasma components; (d) eluting bound immunoglobulins, being anti-Idiotypic antibodies (anti-Id) to autoantibodies, from the matrix; (e) providing a molecular library comprising a plurality of molecule members; and (e) contacting the anti-Id with the molecular library and isolating those bound molecules which are bound by the anti-Id, the bound molecules being molecules which mimic an idiotype of autoantibodies. Also disclosed are such molecules.

The present invention provides multispecific antibodies that bind to EGFR and CD28 (EGFRxCD28) as well as anti-EGFR antibodies. Such antibodies may be combined with a further therapeutic agent such as an anti-PD1 antibody. Methods for treating cancers (e.g., EGFR-expressing cancer) by administering the antibodies (e.g., and combinations thereof with anti-PD1) are also provided. The EGFRxCD28 antibodies of the present invention embody a tumor-targeted immunotherapeutic modality combined with PD-1 inhibition. These bispecific antibodies bind a tumor-specific antigen (TSA) (EGFR) with one arm and the co-stimulatory receptor, CD28, on T-cells with the other arm. Combination therapy with PD-1 inhibitors specifically potentiated intra-tumoral T cell activation, promoting an effector memory-like T cell phenotype without systemic cytokine secretion in a variety of syngeneic and human tumor xenograft models. Combining this class of CD28-co-stimulatory bispecific antibodies with the clinically validated anti-PD-1 treatment provides a well-tolerated antibody therapy with markedly enhanced anti-tumor efficacy.

The invention provides type 1 polarized dendritic cells and an inducing method and application thereof. A novel DC1 preparation method is built through the assistant function of Natural Killer cells of umbilical cord blood in the adaptive immunity activating process of DCs, and in the preparation process, usage of cell factors is reduced, the cost is lowered, and quality control is improved. The invention further provides a method for applying the prepared DC1s to preparation of CTLs with the tumor antigen specificity; after the DC1s are loaded with tumor specific antigens, part of the cells are transfused to a patient body, the other part of the cells are used for in-vitro inductive cytotoxic T lymphocytes (CTL) with the tumor antigen specificity, and the immunoreaction of the tumor specificity is activated through the mode of combining active induction with passive induction in vivo and vitro.